Document is current
Any future updates will be listed below
-
Authors
White, Stephen E.
Schwartze, Tristin A.
Mukundan, Ananya https://orcid.org/0000-0003-1161-4158
Schoenherr, Christina https://orcid.org/0000-0002-0983-6168
Singh, Shashi P. https://orcid.org/0000-0002-6029-8115
van Dinther, Maarten
Cunningham, Kyle T.
White, Madeleine P. J.
Campion, Tiffany https://orcid.org/0009-0002-4010-0762
Pritchard, John https://orcid.org/0000-0002-1812-6985
Hinck, Cynthia S.
ten Dijke, Peter https://orcid.org/0000-0002-7234-342X
Inman, Gareth J. https://orcid.org/0000-0002-6264-4253
Maizels, Rick M.
Hinck, Andrew P. https://orcid.org/0000-0003-3320-8054
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01 GM58670)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R03 AI153915)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (F30 AI157069)
Cancer Research UK (A29802)
Cancer Research UK (A31287)
Wellcome Trust (219530)
- License Information
-
More Information
Article History
Received: 22 March 2024
Accepted: 30 January 2025
First Online: 21 February 2025
Change Date: 17 April 2025
Change Type: Update
Change Details: This article was originally published with the incorrect license 'CC BY-NC-ND 4.0'; it should have been 'CC BY 4.0'. The original article has been corrected.
Competing interests
: A.H. is a member of the scientific advisory board for TCGFB and is a licensee of intellectual property to Kalivir Immunotherapeutics. The remaining authors declare no competing interests.
